Cifurtilimab (SEA-CD40) is a humanised monoclonal antibody acting as a CD40 agonist. It enhances binding to activated FcγRIIIa, exhibiting anticancer activity for treating pancreatic cancer, advanced solid tumours, and lymphoma.

Cifurtilimab enhances FcγRIIIa binding (10-fold higher than parental IgG1 antibodies), bolstering effector functions, resulting in a stronger immunostimulatory activity compared to antibodies with silenced or selective FcγR binding [1]. Exposure to Cifurtilimab elicits distinct response features, such as the activation of APCs, CD8+ and CD4+ T cells, NK cells, and targeted depletion of CD40+ B cells [1].

In preclinical murine models, the combined use of Cifurtilimab with chemotherapy agents enhanced antitumor activity [2].

Human

Monoclonal

Unconjugated